##common.pageHeaderLogo.altText##
DOI:
https://doi.org/10.57187/5395

Medical guidelines

Vol. 156 No. 9 (2026)

2026 Swiss Society for Infectious Diseases recommendations for Clostridioides difficile infection

Cite this as:
Swiss Med Wkly. 2026;156:5395
Published
01.09.2026

Summary

The most recent Swiss Society for Infectious Diseases recommendations for Clostridioides difficile infection (CDI) in Switzerland were based on the 2018 American guidelines. Since then, a large number of new studies have been published, and updated international guidelines – both European and American – have introduced substantial innovations in CDI diagnosis and treatment.

This document represents a consensus statement developed by a group of experts appointed by the Swiss Society for Infectious Diseases. The objective of these national guidelines is to provide a comprehensive, evidence-based and context-specific framework for the diagnosis, treatment, prevention and follow-up of CDI across all stages of disease. By synthesising the latest clinical evidence, recent international guideline updates, and national organisational and regulatory considerations, these guidelines aim to harmonise clinical practice, promote high-quality and equitable patient care and support clinicians in making informed, patient-centred decisions within the Swiss healthcare system. These guidelines are endorsed by the Swiss Society for Infectious Diseases.

References

  1. 1. Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015 Apr;372(16):1539–48. 10.1056/nejmra1403772 doi: https://doi.org/10.1056/NEJMra1403772
  2. 2. Smits WK, Garey KW, Riley TV, Han YW, Young VB, Heritage J, et al. Clostridioides difficile should be considered a bacterial priority pathogen. Lancet Microbe. 2025 Nov;6(11):101184. 10.1016/j.lanmic.2025.101184
  3. 3. van Prehn J, Kuijper EJ, Dubberke ER. Recurrent Clostridioides difficile Infections. JAMA. 2025 Dec;334(23):2128–9. 10.1001/jama.2025.18089
  4. 4 Prehn J van, Reigadas E, Vogelzang EH, et al. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infec 2021. https://doi.org/10.1016/j.cmi.2021.09.038.
  5. 5. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018 Mar;66(7):e1–48. 10.1093/cid/cix1085
  6. 6. Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, et al. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol. 2021 Jun;116(6):1124–47. 10.14309/ajg.0000000000001278
  7. 7. Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis. 2021 Sep;73(5):755–7. 10.1093/cid/ciab718
  8. 8. Hoffmann DE, Javitt GH, Kelly CR, Keller JJ, Baunwall SM, Hvas CL. Fecal microbiota transplantation: a tale of two regulatory pathways. Gut Microbes. 2025 Dec;17(1):2493901. 10.1080/19490976.2025.2493901
  9. 9. Knoop FC, Owens M, Crocker IC. Clostridium difficile: clinical disease and diagnosis. Clin Microbiol Rev. 1993 Jul;6(3):251–65. 10.1128/cmr.6.3.251 doi: https://doi.org/10.1128/CMR.6.3.251
  10. 10. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Jama, vol. 315, 2016, p. 801 810. https://doi.org/10.1001/jama.2016.0287
  11. 11. Miller JM, Binnicker MJ, Campbell S, Carroll KC, Chapin KC, Gonzalez MD, et al. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). Clin Infect Dis. 2024 Mar;•••:ciae104. 10.1093/cid/ciae104
  12. 12. Freeman J, Wilcox MH. The effects of storage conditions on viability of Clostridium difficile vegetative cells and spores and toxin activity in human faeces. J Clin Pathol. 2003 Feb;56(2):126–8. doi: https://doi.org/10.1136/jcp.56.2.126
  13. 13. Schora DM, Peterson LR, Usacheva EA. Immunological Stability of Clostridium difficile Toxins in Clinical Specimens. Infect Control Hosp Epidemiol. 2018 Apr;39(4):434–8. 10.1017/ice.2018.20
  14. 14. Crobach MJ, Planche T, Eckert C, Barbut F, Terveer EM, Dekkers OM, et al. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2016 Aug;22 Suppl 4:S63–81. 10.1016/j.cmi.2016.03.010
  15. 15. Senchyna F, Gaur RL, Gombar S, Truong CY, Schroeder LF, Banaei N. Clostridium difficile PCR Cycle Threshold Predicts Free Toxin. J Clin Microbiol. 2017 Sep;55(9):2651–60. 10.1128/jcm.00563-17 doi: https://doi.org/10.1128/JCM.00563-17
  16. 16. Crobach MJ, Duszenko N, Terveer EM, Verduin CM, Kuijper EJ. Nucleic Acid Amplification Test Quantitation as Predictor of Toxin Presence in Clostridium difficile Infection. J Clin Microbiol. 2018 Feb;56(3):95. 10.1128/jcm.01316-17 doi: https://doi.org/10.1128/JCM.01316-17
  17. 17. Asempa TE, Nicolau DP. Clostridium difficile infection in the elderly: an update on management. Clin Interv Aging. 2017 Oct;12:1799–809. 10.2147/cia.s149089 doi: https://doi.org/10.2147/CIA.S149089
  18. 18. Gilboa M, Regev-Yochay G, Meltzer E, Cohen I, Peretz Y, Zilberman-Daniels T, et al. Antibiotic Use and the Risk of Hospital-Onset Clostridioides Difficile Infection. JAMA Netw Open. 2025 Aug;8(8):e2525252. 10.1001/jamanetworkopen.2025.25252
  19. 19. Vardakas KZ, Konstantelias AA, Loizidis G, Rafailidis PI, Falagas ME. Risk factors for development of Clostridium difficile infection due to BI/NAP1/027 strain: a meta-analysis. Int J Infect Dis. 2012 Nov;16(11):e768–73. 10.1016/j.ijid.2012.07.010
  20. 20. Miller AC, Arakkal AT, Sewell DK, Segre AM, Tholany J, Polgreen PM; CDC MInD-Healthcare Group. Comparison of Different Antibiotics and the Risk for Community-Associated Clostridioides difficile Infection: A Case-Control Study. Open Forum Infect Dis. 2023 Aug;10(8):ofad413. 10.1093/ofid/ofad413
  21. 21. Esme M, Topeli A, Yavuz BB, Akova M. Infections in the Elderly Critically-Ill Patients. Front Med (Lausanne). 2019 Jun;6:118. 10.3389/fmed.2019.00118
  22. 22. Furuya-Kanamori L, Stone JC, Clark J, McKenzie SJ, Yakob L, Paterson DL, et al. Comorbidities, Exposure to Medications, and the Risk of Community-Acquired Clostridium difficile Infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2015 Feb;36(2):132–41. 10.1017/ice.2014.39
  23. 23. Morrison RH, Hall NS, Said M, Rice T, Groff H, Brodine SK, et al. Risk factors associated with complications and mortality in patients with Clostridium difficile infection. Clin Infect Dis. 2011 Dec;53(12):1173–8. 10.1093/cid/cir668
  24. 24. Messick CA, Hammel JP, Hull T. Risk Factors that Predict Recurrent Clostridium difficile Infections in Surgical Patients. Am Surg. 2017 Jun;83(6):653–9. doi: https://doi.org/10.1177/000313481708300633
  25. 25. D’Agostino RB Sr, Collins SH, Pencina KM, Kean Y, Gorbach S. Risk estimation for recurrent Clostridium difficile infection based on clinical factors. Clin Infect Dis. 2014 May;58(10):1386–93. 10.1093/cid/ciu107
  26. 26. van Rossen TM, Ooijevaar RE, Vandenbroucke-Grauls CM, Dekkers OM, Kuijper EJ, Keller JJ, et al. Prognostic factors for severe and recurrent Clostridioides difficile infection: a systematic review. Clin Microbiol Infect. 2022 Mar;28(3):321–31. 10.1016/j.cmi.2021.09.026
  27. 27 Johnson S, Louie TJ, Gerding DN, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 1 AD;59:345–54. https://doi.org/10.1093/cid/ciu313.
  28. 28. Allegretti JR, Marcus J, Storm M, Sitko J, Kennedy K, Gerber GK, et al. Clinical Predictors of Recurrence After Primary Clostridioides difficile Infection: A Prospective Cohort Study. Dig Dis Sci. 2020 Jun;65(6):1761–6. 10.1007/s10620-019-05900-3
  29. 29. Beinortas T, Burr NE, Wilcox MH, Subramanian V. Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis. Lancet Infect Dis. 2018 Sep;18(9):1035–44. 10.1016/s1473-3099(18)30285-8 doi: https://doi.org/10.1016/S1473-3099(18)30285-8
  30. 30. Stabholz Y, Paul M. The effect of antibiotic therapy for Clostridioides difficile infection on mortality and other patient-relevant outcomes: a systematic review and meta-analysis. Clin Microbiol Infect. 2024 Jan;30(1):51–8. 10.1016/j.cmi.2023.09.002
  31. 31 Stevens VW, Nelson RE, Schwab-Daugherty EM, et al. Comparative Effectiveness of Vancomycin and Metronidazole for the Prevention of Recurrence and Death in Patients With Clostridium difficileInfection. Jama Intern Med 2017;177:546 8. https://doi.org/10.1001/jamainternmed.2016.9045.
  32. 32. Doan TH, Yen-Nicolaÿ S, Bernet-Camard MF, Martin-Verstraete I, Péchiné S. Impact of subinhibitory concentrations of metronidazole on proteome of Clostridioides difficile strains with different levels of susceptibility. PLoS One. 2020 Nov;15(11):e0241903. 10.1371/journal.pone.0241903
  33. 33. Krutova M, Wilcox M, Kuijper E. Clostridioides difficile infection: are the three currently used antibiotic treatment options equal from pharmacological and microbiological points of view? Int J Infect Dis. 2022 Nov;124:118–23. 10.1016/j.ijid.2022.09.013
  34. 34. Burton HE, Mitchell SA, Watt M. A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection. PharmacoEconomics. 2017 Nov;35(11):1123–40. 10.1007/s40273-017-0540-2
  35. 35. Tashiro S, Mihara T, Sasaki M, Shimamura C, Shimamura R, Suzuki S, et al. Oral fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection: A systematic review and meta-analysis of randomized controlled trials. J Infect Chemother. 2022 Nov;28(11):1536–45. 10.1016/j.jiac.2022.08.008
  36. 36. Zhao Z, Wu Y, Geng X, Yuan C, Fu Y, Yang G. Efficacy of fidaxomicin versus vancomycin in the treatment of Clostridium difficile infection: A systematic meta-analysis. Medicine (Baltimore). 2024 Aug;103(32):e39213. 10.1097/md.0000000000039213 doi: https://doi.org/10.1097/MD.0000000000039213
  37. 37. Li Q, Obi E, Marciniak A, Newman R, Whittle I, Kufakwaro J. Clinical and economic outcomes associated with fidaxomicin in comparison to vancomycin, metronidazole, and FMT: A systematic literature review. Medicine (Baltimore). 2024 Dec;103(52):e39219. 10.1097/md.0000000000039219 doi: https://doi.org/10.1097/MD.0000000000039219
  38. 38. Rao K, Zhao Q, Bell J, et al. An Open-Label, Randomized Trial Comparing Fidaxomicin With Oral Vancomycin for the Treatment of Clostridioides difficile Infection in Hospitalized Patients Receiving Concomitant Antibiotics for Concurrent Infections. Clin Infect Dis. 2023;•••:ciad606. 10.1093/cid/ciad606
  39. 39. Sehgal K, Zandvakili I, Tariq R, Pardi DS, Khanna S. Systematic Review and Meta-Analysis: Efficacy of Vancomycin Taper and Pulse Regimens in Clostridioides difficile Infection. Expert Rev Anti Infect Ther. 2022 Apr;20(4):577–83. 10.1080/14787210.2022.1997588
  40. 40. Pearlmutter BS, Carlisle MG, Wilson BM, Sangwan N, Donskey CJ. Pulsed dosing and extended daily dosing of oral vancomycin do not facilitate clearance of Clostridioides difficile colonization in mice. Antimicrob Agents Chemother. 2024 Jan;68(1):e0090323. 10.1128/aac.00903-23
  41. 41. Zhang K, Beckett P, Abouanaser S, Stankus V, Lee C, Smieja M. Prolonged oral vancomycin for secondary prophylaxis of relapsing Clostridium difficile infection. BMC Infect Dis. 2019 Jan;19(1):51. 10.1186/s12879-019-3676-1
  42. 42. McDonald EG, Butler-Laporte G, Brophy JM, Elsayed S, Frenette C, Huseen I, et al.; TAPER-V Team. Initial Vancomycin Taper for the Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial. JAMA Netw Open. 2026 Feb;9(2):e2560495. 10.1001/jamanetworkopen.2025.60495
  43. 43. Peery AF, Kelly CR, Kao D, Vaughn BP, Lebwohl B, Singh S, et al.; AGA Clinical Guidelines Committee. Electronic address: clinicalpractice@gastro.org. AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases. Gastroenterology. 2024 Mar;166(3):409–34. 10.1053/j.gastro.2024.01.008
  44. 44. Guery B, Menichetti F, Anttila VJ, Adomakoh N, Aguado JM, Bisnauthsing K, et al.; EXTEND Clinical Study Group. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. Lancet Infect Dis. 2018 Mar;18(3):296–307. 10.1016/s1473-3099(17)30751-x doi: https://doi.org/10.1016/S1473-3099(17)30751-X
  45. 45. Tomas ME, Mana TS, Wilson BM, Nerandzic MM, Joussef-Piña S, Quiñones-Mateu ME, et al. Tapering Courses of Oral Vancomycin Induce Persistent Disruption of the Microbiota That Provide Colonization Resistance to Clostridium difficile and Vancomycin-Resistant Enterococci in Mice. Antimicrob Agents Chemother. 2018 Apr;62(5):e02237–17. 10.1128/aac.02237-17 doi: https://doi.org/10.1128/AAC.02237-17
  46. 46 Louie TJ, Cannon K, Byrne B, et al. Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI. Clin Infect Dis 1 AD;55:S132–42. https://doi.org/10.1093/cid/cis338.
  47. 47. Yamaguchi T, Konishi H, Aoki K, Ishii Y, Chono K, Tateda K. The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin. J Infect Chemother. 2020 May;26(5):483–91. 10.1016/j.jiac.2019.12.020
  48. 48. Deshpande A, Hurless K, Cadnum JL, Chesnel L, Gao L, Chan L, et al. Effect of Fidaxomicin versus Vancomycin on Susceptibility to Intestinal Colonization with Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice. Antimicrob Agents Chemother. 2016 Jun;60(7):3988–93. 10.1128/aac.02590-15 doi: https://doi.org/10.1128/AAC.02590-15
  49. 49. Ajami NJ, Cope JL, Wong MC, Petrosino JF, Chesnel L. Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice. Antimicrob Agents Chemother. 2018 Apr;62(5):e02112–7. 10.1128/aac.02112-17 doi: https://doi.org/10.1128/AAC.02112-17
  50. 50. Gergely Szabo B, Kadar B, Szidonia Lenart K, Dezsenyi B, Kunovszki P, Fried K, et al. Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort study. Clin Microbiol Infect. 2016 Dec;22(12):990–5. 10.1016/j.cmi.2016.08.017
  51. 51. Kechagias KS, Chorepsima S, Triarides NA, Falagas ME. Tigecycline for the treatment of patients with Clostridium difficile infection: an update of the clinical evidence. Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1053–8. 10.1007/s10096-019-03756-z
  52. 52. Phillips EC, Warren CA, Ma JZ, Madden GR. Impact of Tigecycline on C. difficile Outcomes: Case Series and Propensity-Matched Retrospective Study. Antimicrob Agents Chemother. 2022 Jun;66(6):e0000122. 10.1128/aac.00001-22
  53. 53. Larson KC, Belliveau PP, Spooner LM. Tigecycline for the treatment of severe Clostridium difficile infection. Ann Pharmacother. 2011 Jul;45(7-8):1005–10. 10.1345/aph.1q080 doi: https://doi.org/10.1345/aph.1Q080
  54. 54. Herpers BL, Vlaminckx B, Burkhardt O, Blom H, Biemond-Moeniralam HS, Hornef M, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis. 2009 Jun;48(12):1732–5. 10.1086/599224
  55. 55. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013 Jan;368(5):407–15. 10.1056/nejmoa1205037 doi: https://doi.org/10.1056/NEJMoa1205037
  56. 56 Kelly CR, Khoruts A, Staley C, et al. Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection: A Randomized Trial. Ann Intern Med 1 AD;165:609–16. https://doi.org/10.7326/m16-0271. doi: https://doi.org/10.7326/M16-0271
  57. 57. Hvas CL, Dahl Jørgensen SM, Jørgensen SP, Storgaard M, Lemming L, Hansen MM, et al. Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection. Gastroenterology. 2019 Apr;156(5):1324–1332.e3. 10.1053/j.gastro.2018.12.019
  58. 58 Kao D, Roach B, Silva M, et al. Effect of Oral Capsule– vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficileInfection. Jama 2017;318:1985 2. https://doi.org/10.1001/jama.2017.17077.
  59. 59. Vaughn BP, Fischer M, Kelly CR, Allegretti JR, Graiziger C, Thomas J, et al. Effectiveness and Safety of Colonic and Capsule Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. Clin Gastroenterol Hepatol. 2023 May;21(5):1330–1337.e2. 10.1016/j.cgh.2022.09.008
  60. 60. Minkoff NZ, Aslam S, Medina M, Tanner-Smith EE, Zackular JP, Acra S, et al. Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile). Cochrane Database Syst Rev. 2023 Apr;4(4):CD013871. 10.1002/14651858.cd013871.pub2 doi: https://doi.org/10.1002/14651858.CD013871.pub2
  61. 61 Quraishi MN, Widlak M, Bhala N, et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficileinfection. Aliment Pharm Therap 2017;46:479 493. https://doi.org/10.1111/apt.14201.
  62. 62. Svensson CK, Cold F, Ribberholt I, Zangenberg M, Mirsepasi-Lauridsen HC, Petersen AM, et al. The Efficacy of Faecal Microbiota Transplant and Rectal Bacteriotherapy in Patients with Recurrent Clostridioides difficile Infection: A Retrospective Cohort Study. Cells. 2022 Oct;11(20):3272. 10.3390/cells11203272
  63. 63. Poylin V, Hawkins AT, Bhama AR, Boutros M, Lightner AL, Khanna S, et al.; Prepared by the Clinical Practice Guidelines Committee of The American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Clostridioides difficile Infection. Dis Colon Rectum. 2021 Jun;64(6):650–68. 10.1097/dcr.0000000000002047 doi: https://doi.org/10.1097/DCR.0000000000002047
  64. 64. Juul FE, Bretthauer M, Johnsen PH, Samy F, Tonby K, Berdal JE, et al. Fecal Microbiota Transplantation Versus Vancomycin for Primary Clostridioides difficile Infection : A Randomized Controlled Trial. Ann Intern Med. 2025 Jul;178(7):940–7. 10.7326/annals-24-03285 doi: https://doi.org/10.7326/ANNALS-24-03285
  65. 65. Baunwall SM, Andreasen SE, Hansen MM, Kelsen J, Høyer KL, Rågård N, et al. Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2022 Dec;7(12):1083–91. 10.1016/s2468-1253(22)00276-x doi: https://doi.org/10.1016/S2468-1253(22)00276-X
  66. 66. Aby ES, Vaughn BP, Enns EA, Rajasingham R. Cost-effectiveness of fecal microbiota transplantation for first recurrent Clostridioides difficile infection. Clin Infect Dis. 2022 Oct;75(9):1602–9. 10.1093/cid/ciac207
  67. 67. Marcella C, Cui B, Kelly CR, Ianiro G, Cammarota G, Zhang F. Systematic review: the global incidence of faecal microbiota transplantation-related adverse events from 2000 to 2020. Aliment Pharmacol Ther. 2021 Jan;53(1):33–42. 10.1111/apt.16148
  68. 68. Yau YK, Lau LH, Lui RN, Wong SH, Guo CL, Mak JW, et al. Long-Term Safety Outcomes of Fecal Microbiota Transplantation: Real-World Data Over 8 Years From the Hong Kong FMT Registry. Clin Gastroenterol Hepatol. 2024 Mar;22(3):611–620.e12. 10.1016/j.cgh.2023.09.001
  69. 69. Perler BK, Chen B, Phelps E, Allegretti JR, Fischer M, Ganapini V, et al. Long-Term Efficacy and Safety of Fecal Microbiota Transplantation for Treatment of Recurrent Clostridioides difficile Infection. J Clin Gastroenterol. 2020 Sep;54(8):701–6. 10.1097/mcg.0000000000001281 doi: https://doi.org/10.1097/MCG.0000000000001281
  70. 70. Saha S, Mara K, Pardi DS, Khanna S. Long-term Safety of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. Gastroenterology. 2021 May;160(6):1961–1969.e3. 10.1053/j.gastro.2021.01.010
  71. 71. Dawwas GK, Brensinger CM, Vajravelu RK, Wu Q, Kelly CR, Laine L, et al. Long-term Outcomes Following Multiply Recurrent Clostridioides difficile Infection and Fecal Microbiota Transplantation. Clin Gastroenterol Hepatol. 2022 Apr;20(4):806–816.e6. 10.1016/j.cgh.2020.12.004
  72. 72. Gupta S, Mullish BH, Allegretti JR. Fecal Microbiota Transplantation: The Evolving Risk Landscape. Am J Gastroenterol. 2021 Apr;116(4):647–56. 10.14309/ajg.0000000000001075
  73. 73. Berry P, Tariq R, Pardi D, et al. Effectiveness and Safety of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Immunocompromised Patients. Clin Gastroenterol Hepatol. 2025;•••: 10.1016/j.cgh.2025.06.043
  74. 74. Zhao Z, Wu Y, Geng X, Yuan C, Fu Y, Yang G. Efficacy of fidaxomicin versus vancomycin in the treatment of Clostridium difficile infection: A systematic meta-analysis. Medicine (Baltimore). 2024 Aug;103(32):e39213. 10.1097/md.0000000000039213 doi: https://doi.org/10.1097/MD.0000000000039213
  75. 75. Gentry CA, Nguyen PK, Thind S, Kurdgelashvili G, Skrepnek GH, Williams RJ 2nd. Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study. Clin Microbiol Infect. 2019 Aug;25(8):987–93. 10.1016/j.cmi.2018.12.007
  76. 76. Cammarota G, Masucci L, Ianiro G, Bibbò S, Dinoi G, Costamagna G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015 May;41(9):835–43. 10.1111/apt.13144
  77. 77. Tixier EN, Verheyen E, Luo Y, Grinspan LT, Du CH, Ungaro RC, et al. Systematic Review with Meta-Analysis: Fecal Microbiota Transplantation for Severe or Fulminant Clostridioides difficile. Dig Dis Sci. 2022 Mar;67(3):978–88. 10.1007/s10620-021-06908-4
  78. 78. Tixier EN, Verheyen E, Ungaro RC, Grinspan AM. Faecal microbiota transplant decreases mortality in severe and fulminant Clostridioides difficile infection in critically ill patients. Aliment Pharmacol Ther. 2019 Nov;50(10):1094–9. 10.1111/apt.15526
  79. 79. Feuerstadt P, Louie TJ, Lashner B, Wang EE, Diao L, Bryant JA, et al. SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med. 2022 Jan;386(3):220–9. 10.1056/nejmoa2106516 doi: https://doi.org/10.1056/NEJMoa2106516
  80. 80. Blair HA. SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection. Drugs. 2024 Mar;84(3):329–36. 10.1007/s40265-024-02006-7
  81. 81. Khanna S, Assi M, Lee C, Yoho D, Louie T, Knapple W, et al. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection. Drugs. 2022 Oct;82(15):1527–38. 10.1007/s40265-022-01797-x
  82. 82. Louie T, Golan Y, Khanna S, Bobilev D, Erpelding N, Fratazzi C, et al. VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial. JAMA. 2023 Apr;329(16):1356–66. 10.1001/jama.2023.4314
  83. 83. Tschudin-Sutter S, Kuijper EJ, Durovic A, Vehreschild MJ, Barbut F, Eckert C, et al.; Committee. Guidance document for prevention of Clostridium difficile infection in acute healthcare settings. Clin Microbiol Infect. 2018 Oct;24(10):1051–4. 10.1016/j.cmi.2018.02.020
  84. 84. Webb BJ, Subramanian A, Lopansri B, et al. Antibiotic Exposure and Risk for Hospital-Associated Clostridioides difficile Infection. Antimicrob Agents Chemother 2020;64:10.1128/aac.02169-19. https://doi.org/10.1128/aac.02169-19. doi: https://doi.org/10.1128/AAC.02169-19
  85. 85. Liu Y, Dai M, Zhang K, Zhang L, Lin B, Chen K, et al. Risk of Clostridioides difficile infection following different antibiotics: insights from multi-source medical data. Int J Antimicrob Agents. 2024 Oct;64(4):107288. 10.1016/j.ijantimicag.2024.107288
  86. 86. Di Bella S, Sanson G, Monticelli J, Zerbato V, Principe L, Giuffrè M, et al. Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options. Clin Microbiol Rev. 2024 Jun;37(2):e0013523. 10.1128/cmr.00135-23
  87. 87. Miller AC, Arakkal AT, Sewell DK, Segre AM, Tholany J, Polgreen PM; CDC MInD-Healthcare Group. CDC MInD-Healthcare Group. Comparison of different antibiotics and the risk for community-associated Clostridioides difficile infection: a case–control study. Open Forum Infect Dis. 2023 Aug;10(8):ofad413. 10.1093/ofid/ofad413
  88. 88. Webb BJ, Subramanian A, Lopansri B, Goodman B, Jones PB, Ferraro J, et al. Antibiotic exposure and risk for hospital-associated Clostridioides difficile infection. Antimicrob Agents Chemother. 2020 Mar;64(4):e02169–19. 10.1128/AAC.02169-19
  89. 89. Liu Y, Dai M, Zhang K, Zhang L, Lin B, Chen K, et al. Risk of Clostridioides difficile infection following different antibiotics: insights from multi-source medical data. Int J Antimicrob Agents. 2024 Oct;64(4):107288. 10.1016/j.ijantimicag.2024.107288
  90. 90. Ray MJ, Strnad LC, Tucker KJ, Furuno JP, Lofgren ET, McCracken CM, et al. Influence of Antibiotic Exposure Intensity on the Risk of Clostridioides difficile Infection. Clin Infect Dis. 2024 Nov;79(5):1129–35. 10.1093/cid/ciae259
  91. 91. Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother. 2013 May;57(5):2326–32. 10.1128/aac.02176-12 doi: https://doi.org/10.1128/AAC.02176-12
  92. 92. Azab M, Doo L, Doo DH, Elmofti Y, Ahmed M, Cadavona JJ, et al. Comparison of the Hospital-Acquired Clostridium difficile Infection Risk of Using Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists for Prophylaxis and Treatment of Stress Ulcers: A Systematic Review and Meta-Analysis. Gut Liver. 2017 Nov;11(6):781–8. 10.5009/gnl16568
  93. 93. Eeuwijk J, Ferreira G, Yarzabal JP, Robert-Du Ry van Beest Holle M. A Systematic Literature Review on Risk Factors for and Timing of Clostridioides difficile Infection in the United States. Infect Dis Ther. 2024 Feb;13(2):273–98. 10.1007/s40121-024-00919-0
  94. 94. Finke M, Boven A, Vlieghe E, Engstrand L, Orsini N, Brusselaers N. Proton pump inhibitors and the risk of Clostridioides difficile infection: A systematic review and dose-response meta-analysis. J Infect. 2025 May;90(5):106488. 10.1016/j.jinf.2025.106488
  95. 95. Floria DE, Obeidat M, Váncsa S, Kávási SB, Földvári-Nagy L, Hegyi P, et al. Proton pump inhibitors are not associated with an increased risk of Clostridioides difficile infection: a systematic review and meta-analysis of randomized controlled trials. Gut Microbes. 2025 Dec;17(1):2562341. 10.1080/19490976.2025.2562341
  96. 96. Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, et al.; COMPASS Investigators. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology. 2019 Sep;157(3):682–691.e2. 10.1053/j.gastro.2019.05.056
  97. 97. Anjewierden S, Han Z, Brown AM, Donskey CJ, Deshpande A. Risk factors for Clostridioides difficile colonization among hospitalized adults: A meta-analysis and systematic review. Infect Control Hosp Epidemiol. 2021 May;42(5):565–72. 10.1017/ice.2020.1236
  98. 98. Cannon CM, Musuuza JS, Barker AK, Duster M, Juckett MB, Pop-Vicas AE, et al. Risk of Clostridium difficile Infection in Hematology-Oncology Patients Colonized With Toxigenic C. difficile. Infect Control Hosp Epidemiol. 2017 Jun;38(6):718–20. 10.1017/ice.2017.48
  99. 99. Ford CD, Lopansri BK, Webb BJ, Coombs J, Gouw L, Asch J, et al. Clostridioides difficile colonization and infection in patients with newly diagnosed acute leukemia: Incidence, risk factors, and patient outcomes. Am J Infect Control. 2019 Apr;47(4):394–9. 10.1016/j.ajic.2018.09.027
  100. 100. Fuereder T, Koni D, Gleiss A, Kundi M, Makristathis A, Zielinski C, et al. Risk factors for Clostridium difficile infection in hemato-oncological patients: A case control study in 144 patients. Sci Rep. 2016 Aug;6(1):31498. 10.1038/srep31498
  101. 101. Milenković B, Šuljagić V, Perić A, Dragojević-Simić V, Tarabar O, Milanović M, et al. Outcomes of Clostridioides difficile infection in adult cancer and non-cancer patients hospitalised in a tertiary hospital: a prospective cohort study. Eur J Hosp Pharm. 2022 Mar;29 e1:e15–22. 10.1136/ejhpharm-2020-002574
  102. 102. Larrainzar-Coghen T, Rodríguez-Pardo D, Barba P, Aguilar-Company J, Rodríguez V, Roig G, et al. Prognosis of Clostridium difficile infection in adult oncohaematological patients: experience from a large prospective observational study. Eur J Clin Microbiol Infect Dis. 2018 Nov;37(11):2075–82. 10.1007/s10096-018-3341-4
  103. 103. De-la-Rosa-Martinez D, Zinser-Peniche P, Martin-Onraet A, Rivera-Buendía F, Vilar-Compte D. Performance of Clostridioides difficile infection severity scores and risk factors related to 30-day all-cause mortality in patients with cancer. Support Care Cancer. 2023 Feb;31(3):187. 10.1007/s00520-023-07651-4
  104. 104. Hung YP, Tsai CS, Tsai BY, Tsai PJ, Lee YT, Lee JC, et al. Clostridioides difficile infection in patients with hematological malignancy: A multicenter study in Taiwan. J Microbiol Immunol Infect. 2021 Dec;54(6):1101–10. 10.1016/j.jmii.2021.02.002

Most read articles by the same author(s)

<< < 1 2 3 4